Workflow
Cullinan Oncology(CGEM) - 2025 Q1 - Quarterly Results
CGEMCullinan Oncology(CGEM)2025-05-08 11:21

Clinical Trials and Approvals - Cullinan Therapeutics received EMA approval for CLN-978; Phase 1 study in difficult-to-treat rheumatoid arthritis to start in Q2 2025[1] - The company plans to initiate a Phase 1 study for CLN-978 in Sjögren's disease in the U.S. in Q2 2025[1] - The pivotal Phase 2b portion of the REZILIENT1 study of zipalertinib met the primary endpoint of overall response rate[3] - The company expects to deliver initial clinical data in systemic lupus erythematosus by the end of 2025[2] - CLN-619 development in gynecological cancers has been discontinued due to preliminary results not meeting internal advancement thresholds[6] Financial Performance - Cash position as of March 31, 2025, was 567.4million,providingarunwayinto2028[9]−ResearchanddevelopmentexpensesforQ12025were567.4 million, providing a runway into 2028[9] - Research and development expenses for Q1 2025 were 41.5 million, up from 30.6millioninQ12024[9]−GeneralandadministrativeexpensesforQ12025were30.6 million in Q1 2024[9] - General and administrative expenses for Q1 2025 were 13.5 million, compared to 12.3millioninQ12024[9]−NetlossattributabletoCullinanforQ12025was12.3 million in Q1 2024[9] - Net loss attributable to Cullinan for Q1 2025 was 48.5 million, compared to 37.1millioninQ12024[9]−TotaloperatingexpensesforQ12025were37.1 million in Q1 2024[9] - Total operating expenses for Q1 2025 were 55.0 million, compared to $43.0 million in Q1 2024[9]